Leerink Partnrs Brokers Decrease Earnings Estimates for CRSP

Key Points

• Leerink Partners has decreased its Q3 2025 earnings per share estimate for CRISPR Therapeutics from ($1.59) to ($1.62), reflecting a cautious outlook for the company's financial performance.
• Wall Street analysts have mixed views on CRISPR Therapeutics, with a target price range between $42.00 and $105.00, leading to an average rating of "Hold" for the stock.
• CRISPR Therapeutics reported a Q2 earnings of ($1.29) per share, exceeding estimates but falling short on revenue expectations, generating only $0.89 million against a forecast of $6.44 million.

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings per share (EPS) estimates for CRISPR Therapeutics in a report released on Monday, August 4th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($1.62) for the quarter, down from their previous forecast of ($1.59). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics' Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($5.52) EPS and FY2026 earnings at ($5.53) EPS.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%. The firm had revenue of $0.89 million for the quarter, compared to analysts' expectations of $6.44 million. During the same quarter last year, the business earned ($1.49) earnings per share. The company's revenue was up 72.5% compared to the same quarter last year.

CRSP has been the topic of a number of other research reports. Needham & Company LLC reissued a "buy" rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. Wall Street Zen upgraded CRISPR Therapeutics to a "sell" rating in a research note on Friday, May 16th. HC Wainwright boosted their price target on CRISPR Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research note on Thursday. Chardan Capital restated a "buy" rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday. Finally, The Goldman Sachs Group dropped their price objective on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $71.60.

CRISPR Therapeutics Trading Down 1.7%

Shares of NASDAQ CRSP traded down $0.96 during mid-day trading on Thursday, reaching $55.00. 1,602,286 shares of the company's stock were exchanged, compared to its average volume of 3,641,424. The firm has a market capitalization of $5.00 billion, a price-to-earnings ratio of -10.13 and a beta of 1.80. The business has a fifty day simple moving average of $51.60 and a 200 day simple moving average of $43.92. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $71.13.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. boosted its holdings in CRISPR Therapeutics by 27.5% in the second quarter. Rockefeller Capital Management L.P. now owns 115,356 shares of the company's stock worth $5,611,000 after acquiring an additional 24,853 shares in the last quarter. Intech Investment Management LLC bought a new position in shares of CRISPR Therapeutics in the second quarter valued at approximately $1,896,000. Creative Planning lifted its holdings in shares of CRISPR Therapeutics by 16.7% in the second quarter. Creative Planning now owns 15,841 shares of the company's stock valued at $770,000 after purchasing an additional 2,263 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of CRISPR Therapeutics by 31.2% in the second quarter. SG Americas Securities LLC now owns 38,482 shares of the company's stock valued at $1,872,000 after purchasing an additional 9,141 shares in the last quarter. Finally, Sittner & Nelson LLC lifted its holdings in shares of CRISPR Therapeutics by 13.2% in the second quarter. Sittner & Nelson LLC now owns 4,970 shares of the company's stock valued at $242,000 after purchasing an additional 580 shares in the last quarter. Institutional investors own 69.20% of the company's stock.

Insider Activity

In other CRISPR Therapeutics news, Director Simeon George bought 989,812 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The shares were bought at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the transaction, the director directly owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Naimish Patel sold 3,932 shares of the company's stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the sale, the insider owned 6,068 shares in the company, valued at approximately $218,083.92. The trade was a 39.32% decrease in their position. The disclosure for this sale can be found here. 4.30% of the stock is owned by corporate insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.